Page 71 - CIBERDEM2016-ENG

Most relevant scientific articles
• Tellez N., Vilaseca M., Marti Y., Pla A., Montanya E. β-cell dedifferentiation, reduced duct cell plasticity, and impaired β-cell mass regeneration in middle-aged rats. American Journal of Physiology - Endocrinology and Metabolism. 2016;311(3):E554-E563.
• Soria B., Montanya E., Martín F., Hmadcha A. A role for the host in the roadmap to diabetes stem cell therapy. Diabetes. 2016;65(5):1155-1157.
• Vilarrasa N., de Gordejuela A.G.R., Casajoana A., Duran X., Toro S., Espinet E. et al. Endobarrier® in grade I Obese Patients with Long-Standing Type 2 Diabetes: Role of gastrointestinal Hormones in glucose Metabolism. Obesity Surgery. 2016:1-9.
• Vilarrasa N., Rubio M.A., Minambres I., Flores L., Caixas A., Ciudin A. et al. Long-Term Outcomes in Patients with Morbid Obesity and Type 1 Diabetes Undergoing Bariatric Surgery. Obesity Surgery. 2016;1-8.
• Bartlett ST, Markmann JF, Johnson P, Korsgren O, Hering BJ, Scharp D et al. Report from IPITA-TTS Opinion Leaders Meeting on the Future of β-Cell Replacement. Transplantation. 2016;100 Suppl 2:S1- S44.
Highlights
We have described that aging is associated with a decrease in the ability of expansion of beta mass, with the contribution of both, limitation of neogenesis as well as de-differentiation of beta cells, whereas hypertrophy and beta cell hyperplasia capabilities are maintained. We have also reported that duodenal- yeyunal bypass liner, Endobarrier®, in type 2 diabetes patients with grade I obesity and poor metabolic control is associated with significant weight decrease and moderate reduction in HbA1c at month 12.
The data do not support a role for gLP-1 in the metabolic improvement in this subset of patients. A collaborative clinical trial, of our own initiative, assessing the impact of the optimization of metabolic control in patient with type 1 diabetes mellitus on platelet reactivity has been completed. An observational study of preferences of patients in relation to the treatment of type 2 diabetes has also been completed. The group has participated in the preparation of the document from de International Pancreas and Islet Transplant Association (IPITA) and Transplantation Society (TTS) “Report from the IPITA-TSS Opinion Leaders Meeting on the Future of Beta Cell Replacement”.
The group PI has been member of Organizer Committee of EASD Islet Study group Meeting 2016. The group maintains a high presence in boards of national and international scientific institutions, among them, the Islet Study group de la EASD, el grupo de Islotes de la SED, y la Associació Catalana de Diabetes.
The group PI has been appointed coordinator of Program of Diabetes and Metabolism from the area of Translacional Medicine of IDIBELL. Regarding education, two students have completed their degree project and master project, respectively in 2016. The group has participated in the outreach activity Improciencia from Week of Science, with the presentation of the Project “Beta cells generation”.
DEM
research groups 71